Get the Stockscreener App
0.3135
3.24%
-0.0105
After Hours:
.31
-0.0035
-1.12%
Calidi Biotherapeutics Inc stock is traded at $0.3135, with a volume of 232.66K.
It is down -3.24% in the last 24 hours and down -58.20% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$0.324
Open:
$0.32
24h Volume:
232.66K
Relative Volume:
1.34
Market Cap:
$2.25M
Revenue:
-
Net Income/Loss:
$-25.83M
P/E Ratio:
-0.0465
EPS:
-6.7442
Net Cash Flow:
$-21.77M
1W Performance:
-12.92%
1M Performance:
-58.20%
6M Performance:
-80.65%
1Y Performance:
-96.99%
1-Day Range:
$0.3033
$0.32
1-Week Range:
$0.3033
$0.36
52-Week Range:
$0.3033
$19.20
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.3135 | 2.32M | 0 | -25.83M | -21.77M | -6.7442 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.49 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.05 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
706.03 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.42 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
287.33 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Calidi Biotherapeutics prices $5.2M underwritten public offering - MSN
Can Calidi Biotherapeutics Inc keep up with sector leaders2026 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn
Portfolio Recap: How much upside does Calidi Biotherapeutics Inc have2026 Market Mood & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing - Sahm
Calidi Biotherapeutics Prices Public Offering at $0.50 per Unit - Intellectia AI
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing - Bitget
How a tumor-targeting virus therapy earned FDA support on its production - Stock Titan
Calidi Biotherapeutics Announces Proposed Public Offering of Common Stock and Warrants to Fund Growth Initiatives 12 - Minichart
Calidi Biotherapeutics Completes Dilutive Public Equity Offering - TipRanks
Calidi Biotherapeutics announces underwritten public offering - Investing.com Nigeria
Calidi Biotherapeutics Raises $6.03 Million in Unit Offering; Adds Warrant Agent and Amends Legacy Warrants - TradingView
Calidi Biotherapeutics (NYSE: CLDI) closes $6M unit and warrant deal - Stock Titan
Portfolio Update: Is Calidi Biotherapeutics Inc a stock for growth or value investors2026 Trading Volume Trends & Accurate Buy Signal Alerts - baoquankhu1.vn
CLDI PE Ratio & Valuation, Is CLDI Overvalued - Intellectia AI
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option - Bitget
Calidi Biotherapeutics Announces Closing of $6.0 Million - GlobeNewswire
Calidi Biotherapeutics closes $6M public offering - Investing.com
Calidi Biotherapeutics closes $6M public offering By Investing.com - Investing.com India
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option - The Manila Times
Biotech Calidi raises $6M now, lines up $12M more with new warrants - Stock Titan
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option - GlobeNewswire Inc.
Investor Ognian Gavrilov reports 9.8% Calidi Biotherapeutics (CLDI) stake in Schedule 13D - Stock Titan
Calidi Biotherapeutics Prices $5.2 Mln Public Offering Of Shares And Warrants - Nasdaq
Calidi Biotherapeutics (CLDI) stock plunges 35% after hours — here's why - MSN
Published on: 2026-03-07 11:34:48 - baoquankhu1.vn
Growth Value: Is Calidi Biotherapeutics Inc forming a bullish divergenceTreasury Yields & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Stop Loss: Does Calidi Biotherapeutics Inc have pricing powerJuly 2025 Summary & Daily Chart Pattern Signals - baoquankhu1.vn
Crude Oil Jumps Over 12%; US Retail Sales Fall In January - Benzinga
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering - Bitget
Calidi prices 10.5M units at 50c in underwritten public offering - TipRanks
Calidi Biotherapeutics announces pricing of $5.2 million underwritten public offering - marketscreener.com
Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering - TradingView
Calidi Biotherapeutics announces underwritten public offering By Investing.com - Investing.com Canada
Calidi Biotherapeutics (CLDI) Stock Plunges 35% After HoursHere's Why - Finviz
Calidi Biotherapeutics Announces Public Offering, Shares Plunge 31% - Intellectia AI
Calidi Sinks On Proposed Public Offering; Shares Hit New 52-Week Low - Nasdaq
Calidi Biotherapeutics Announces Proposed Public Offering - The Manila Times
Biotech Calidi plans stock-and-warrant sale for working capital - Stock Titan
Calidi details characterization of CLD-401 for solid tumor treatment - BioWorld MedTech
CLDI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug PreEarnings: Will Calidi Biotherapeutics Inc. stock recover after earningsJuly 2025 Weekly Recap & Daily Stock Trend Reports - baoquankhu1.vn
Quarterly Earnings: Is Calidi Biotherapeutics Inc a stock for growth or value investors - baoquankhu1.vn
CLDICalidi Biotherapeutics Inc Latest Stock News & Market Updates - Stock Titan
Is Calidi Biotherapeutics Inc. a momentum stockQuarterly Growth Report & Technical Entry and Exit Tips - mfd.ru
Can Calidi Biotherapeutics Inc. keep up with sector leadersJuly 2025 Fed Impact & Weekly Top Performers Watchlists - mfd.ru
Will Calidi Biotherapeutics Inc. stock benefit from AI adoptionEarnings Beat & Pattern Based Trade Signal System - mfd.ru
New virus-based tactic aims to revive T-cell engagers for solid tumors - Stock Titan
Will Calidi Biotherapeutics Inc. stock maintain strong growthEarnings Overview Summary & Safe Capital Investment Plans - mfd.ru
Energy Moves: Why analysts remain bullish on Calidi Biotherapeutics Inc. stockJuly 2025 Gainers & Community Verified Trade Signals - mfd.ru
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference - Bitget
Engineered virus from Calidi delivers BiTEs into solid tumors - Stock Titan
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.46%
Cap:
|
Volume (24h):